Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

August

3

TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program

Purchase agreement for up to $250 million in milestone payments plus royalties on future...

30

electroCore Provides Update on Availability of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

Initial distribution to hospitals and patients expected to begin on July 31st BASKING RIDGE,...

28

electroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in Cephalalgia

Paper supports use of nVNS as a front-line therapy for acute and preventative treatment...

28

Exagen Inc. Reports Second Quarter 2020 Results

Testing experiencing monthly sequential improvement; record gross margins of 63% SAN DIEGO, July 28, 2020 (GLOBE...

13

electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

Intended use allows gammaCore Sapphire CV use at home or in a healthcare setting...

17

Exagen and the Ohio State Innovation Foundation Announce Exclusive License Agreement and Research Collaboration

Goal to Develop a Novel, Rule-In, Blood Test to Support the Diagnosis of Fibromyalgia...

3

Exagen Inc. Announces Clinical Trial Conducted at Major Academic Center in Distinguishing Type 1 and Type 2 Lupus

Duke Lupus Clinic is focused on diagnosing, treating, and providing expert care to patients living...

2

Tullis Health Investors Welcomes Bob Crutchfield to Its Team

Tullis Health Investors is pleased to announce the addition of Robert L. Crutchfield as...

14

electroCore Announces First Quarter Financial Results

Generated first quarter revenue of $734,000 Secured FDA clearance of gammaCore™ (nVNS) label expansion for migraine...

11

Exagen Inc. Reports First Quarter 2020 Results

AVISE® Testing Volumes Increase with Retention Rate of 99% SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE)...

11

ATEC Reports First Quarter 2020 Financial Results And Recent Corporate Highlights

• New Product Adoption Drives U.S. Revenue Growth of 27%• Additional $35 Million Capital...

29

electroCore Provides Update on COVID-19 Clinical Initiatives

Randomized controlled investigator-initiated trial (IIT) of non-invasive vagus nerve stimulation (nVNS) therapy currently enrolling...

Recent developments

News

August

3

TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program

July

30

electroCore Provides Update on Availability of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

July

28

electroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in Cephalalgia

July

28

Exagen Inc. Reports Second Quarter 2020 Results

July

13

electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

June

17

Exagen and the Ohio State Innovation Foundation Announce Exclusive License Agreement and Research Collaboration

June

3

Exagen Inc. Announces Clinical Trial Conducted at Major Academic Center in Distinguishing Type 1 and Type 2 Lupus

June

2

Tullis Health Investors Welcomes Bob Crutchfield to Its Team

May

14

electroCore Announces First Quarter Financial Results

May

11

Exagen Inc. Reports First Quarter 2020 Results

May

11

ATEC Reports First Quarter 2020 Financial Results And Recent Corporate Highlights

April

29

electroCore Provides Update on COVID-19 Clinical Initiatives